aHUS Action has been informed that NHS England intends to commission a service for aHUS patients and is currently in the process of developing a service specification.
Recent News and Views
The clinical outcomes for the use of Eculizumab mark a step change in the treatment of aHUS, providing much needed hope for patients and their families after so many years of uncertainty.
Under the draft terms of the recommendations on the use of Soliris in the NHS from NICE, the committee has stated unequivocally that Soliris must be managed via an expert centre to ensure treatment protocols are adhered to but the recommendations fall short of stating whether a full NHS National Highly Specialised Service is needed.
The Committee has rightly recognised that Eculizumab marks a step change for the treatment of aHUS and this initial decision provides much needed hope for patients after many years of uncertainty.